Fabio Cataldi - Sep 5, 2022 Form 4 Insider Report for Landos Biopharma, Inc. (LABP)

Role
Chief Medical Officer
Signature
/s/ Gregory Oakes, Attorney-in-Fact
Stock symbol
LABP
Transactions as of
Sep 5, 2022
Transactions value $
$0
Form type
4
Date filed
9/7/2022, 05:09 PM
Next filing
Mar 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Employee Stock Option (right to buy) Award $0 +400K $0.00 400K Sep 5, 2022 Common Stock 400K $0.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares of common stock underlying this option will vest and become exercisable on September 5, 2023 and the remaining shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.